09.15.10
Stratum Nutrition, in collaboration with its commercialization partner, KitoZyme, has received regulatory (Institutional Review Board) approval for clinical protocol and initiated recruitment and randomization for an additional clinical study on the company's branded chitin-glucan ingredient Artinia.
To build on existing clinical evidence for this novel, vegetarian fiber, Stratum has designed a randomized, double-blind, placebo-controlled, multi-centered clinical study to evaluate the effects of Artinia on the oxidation of LDL (low-density lipoprotein). In addition, this study will assess the effects of Artinia on other established biomarkers of glycemic control, inflammation and human safety.
Artinia is a natural chitin-glucan fiber derived from the mycelium of non-genetically-modified strain of Aspergillus niger, and features the benefits of both soluble and insoluble fibers. A 12-week animal and 30-day human pilot study have been completed, and each study demonstrated that Artinia provided substantial benefits for arterial and overall heart health. For further information: www.stratumnutrition.com; www.kitozyme.com
To build on existing clinical evidence for this novel, vegetarian fiber, Stratum has designed a randomized, double-blind, placebo-controlled, multi-centered clinical study to evaluate the effects of Artinia on the oxidation of LDL (low-density lipoprotein). In addition, this study will assess the effects of Artinia on other established biomarkers of glycemic control, inflammation and human safety.
Artinia is a natural chitin-glucan fiber derived from the mycelium of non-genetically-modified strain of Aspergillus niger, and features the benefits of both soluble and insoluble fibers. A 12-week animal and 30-day human pilot study have been completed, and each study demonstrated that Artinia provided substantial benefits for arterial and overall heart health. For further information: www.stratumnutrition.com; www.kitozyme.com